Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
85 hedge funds and large institutions have $257M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
27% more capital invested
Capital invested by funds: $203M → $257M (+$54.6M)
18% more funds holding
Funds holding: 72 → 85 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$9.89M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$8.58M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$7.47M |
| 4 |
OPU
Omni Partners US
Irvine,
California
|
+$6.57M |
| 5 |
SRF
Silver Rock Financial
Los Angeles,
California
|
+$6.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingstown Capital Management
New York
|
-$2.96M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.96M |
| 3 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$1.98M |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
-$1.56M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.48M |
PEAR Hedge Fund Activity: Q3 2021 in Review
85 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q3 2021, worth a combined $257M — up 27% from $203M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PEAR positions and 8 closed out — a net gain of 13 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was BlueCrest Capital Management, opening a new position worth an estimated $9.89M. The largest seller was Kingstown Capital Management, exiting entirely with an estimated $2.96M sold.
- 85 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q3 2021, up from 72 in Q2 2021.
- Funds reported $257M of Pear Therapeutics, Inc. Class A Common Stock stock for Q3 2021, up 27% quarter-over-quarter.
- 21 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q3 2021 and 8 closed out, a net change of +13 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q3 2021 was BlueCrest Capital Management, an estimated $9.89M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q3 2021 was Kingstown Capital Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q3 2021.